文献速递流行病学与生物统计医学教育与科研方法

试验团队应如何决定其试验中族裔群体的比例与多样性

How should trial teams make decisions about the proportions and diversity of the ethnic groups in their trial?
PubMed 文献 · Trials · 2024-11-15

STRIDE项目涵盖癌症、心血管、糖尿病、孕产妇健康、心理健康和戒烟六个临床领域,与40名专家小组成员讨论了23项试验,旨在为试验者提供关于如何决定试验中应纳入哪些族裔群体及比例的实用信息。小组认为该问题难以回答,核心障碍在于缺乏按族裔划分的患病率公开数据。研究形成八条STRIDE推荐及五项政策倡议。

要点

  • 讨论应涉及多元化团队,需要时间并获取最佳可用数据。
  • 在缺乏数据或共识时,推荐采用「默认」最低纳入比例,并考虑过度抽样。
  • 这些讨论应指导中心选择,招募与保留的实际挑战不应决定纳入哪些群体。

核心结论

  • 就试验中应纳入哪些族裔群体达成目标至关重要但困难重重;若遵循八条推荐,可使试验更具族裔多样性,并建议五项政策倡议以创造支持性实施环境。

研究设计与样本

  • STRIDE项目考虑癌症、心血管、糖尿病、孕产妇健康、心理健康和戒烟六个临床领域的试验。
  • 为每项试验创建总结,包括参与者-干预-对照-结局及按族裔划分的疾病患病率数据。
  • 与具备临床专业知识、试验与方法学专业知识、生活经验、资助经验以及与族裔社区合作经验的专家小组讨论。
  • 与40名专家小组成员讨论了23项试验。

主要发现

  • 专家小组认为所提问题难以回答,核心原因在于缺乏按族裔划分的患病率公开数据。
  • 在有数据可用时,决策更容易但并不简单。
  • 讨论形成了八条STRIDE推荐。

关键数值与推荐

  • 推荐讨论涉及多元化团队,讨论需要时间并获取最佳可用数据。
  • 在缺乏数据或共识时,推荐采用「默认」最低纳入比例,并考虑过度抽样。
  • 这些讨论应指导中心选择,招募与保留的实际挑战不应决定纳入哪些群体。
  • 建议五项政策倡议:(1)资助者需表明期望族裔多样性;(2)试验团队需获取更好的数据;(3)资助者及其他方需表明族裔多样性意味着更好的科学;(4)需要更多资金用于评估;(5)良好临床实践培训应涵盖族裔多样性。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 专家小组认为所提问题难以回答,核心原因在于缺乏按族裔划分的患病率公开数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The benefits of randomised trials are not shared equally, and people from ethnic minority groups are a key constituency under-served by clinical research and clinical care. The STRIDE project aimed to give trialists practical information about how to decide which ethnic groups should be in their trials, and at what proportion. METHODS: We considered trials in six clinical areas: cancer, cardiovascular, diabetes, maternal health, mental health, and smoking cessation. We created a summary for each, including participants-intervention-comparators-outcomes, and data on disease prevalence by ethnicity. These were discussed with panels with clinical expertise, trial and methodology expertise, lived experience, funding, and experience of working with and on behalf of ethnic communities. For each trial, we asked panel members to decide which ethnic groups should have been involved and at what proportion. RESULTS: We discussed 23 trials with 40 individual panel members. Panels found our questions difficult to answer. The lack of publicly available data on prevalence by ethnicity was central to this. Where data were available, decision-making was easier but not simple. The discussions led to eight STRIDE recommendations. We recommend that discussions involve diverse teams and that discussions need time, with access to the best available data. In the absence of data or consensus, we recommend the adoption of 'default' minimum rates of inclusion, with oversampling considered. These discussions should inform site selection, and the practical challenges of recruitment and retention should not determine which groups are to be included. We also suggest five policy initiatives to support implementation of the recommendations. Broadly, these are (1) funders need to signal that ethnic diversity is expected, (2) trial teams need access to better data, (3) funders and others need to signal that ethnic diversity means better science, (4) more funding is needed for evaluation, and (5) Good Clinical Practice training should cover ethnic diversity. CONCLUSIONS: Agreeing targets for which ethnic groups to involve in a trial is essential but difficult. Our eight recommendations could help to make trials more ethnically diverse if followed, and we suggest five policy initiatives that would create a supportive environment for their implementation.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Treweek S, Gillies K, Witham MD, et al. How should trial teams make decisions about the proportions and diversity of the ethnic groups in their trial? Trials. 2024. PMID: 39543747. doi:10.1186/s13063-024-08625-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。